Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018
Purpose: This study aimed to estimate the incidence and prevalence of neovascular age-related macular degeneration (nAMD) in the French population between 2008 and 2018. Design: This was a retrospective, longitudinal population study using health care consumption data from the Système National des D...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-03-01
|
| Series: | Ophthalmology Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666914522000033 |
| _version_ | 1818315374346633216 |
|---|---|
| author | Catherine P. Creuzot-Garcher, MD, PhD Mayer Srour, MD Florian Baudin, MD Vincent Daien, MD, PhD Corinne Dot, MD, PhD Sylvia Nghiem-Buffet, MD Jean-Francois Girmens, MD Nicolas Coulombel, MBA Anne Ponthieux, PhD Cecile Delcourt, PhD |
| author_facet | Catherine P. Creuzot-Garcher, MD, PhD Mayer Srour, MD Florian Baudin, MD Vincent Daien, MD, PhD Corinne Dot, MD, PhD Sylvia Nghiem-Buffet, MD Jean-Francois Girmens, MD Nicolas Coulombel, MBA Anne Ponthieux, PhD Cecile Delcourt, PhD |
| author_sort | Catherine P. Creuzot-Garcher, MD, PhD |
| collection | DOAJ |
| description | Purpose: This study aimed to estimate the incidence and prevalence of neovascular age-related macular degeneration (nAMD) in the French population between 2008 and 2018. Design: This was a retrospective, longitudinal population study using health care consumption data from the Système National des Données de Santé (SNDS; the French National Health Information Database), which covers approximately 99% of the French population. Participants: We identified individuals treated for nAMD from the French population 50 years of age and older. Identification criteria were nAMD diagnosis or reimbursement of nAMD treatments (anti–vascular endothelial growth factor intravitreal injection or dynamic phototherapy with verteporfin). Exclusion criteria were high myopia, diagnosis of other retinal diseases, and other treatments for macular diseases (dexamethasone implant, laser therapy, etc.). Methods: We calculated incidence and prevalence based on the age-matched general population in France. Adjustment for age and sex was also performed for incidence. Main Outcome Measures: Incidence and prevalence of nAMD in the French population between 2008 and 2018. Results: Between 2008 and 2018, we identified 342 961 patients with nAMD (67.5% women). Mean ± standard deviation age at nAMD diagnosis or first treatment increased from 78.8 ± 8.1 years in 2008 to 81.2 ± 7.9 years in 2018. In 2018, annual incidence was 0.149% and prevalence was 1.062% for the French population 50 years of age or older. Incidence was stable over the 10-year period. Annual incidence increased with age (0.223%, 0.380%, and 0.603% in those 60 years of age or older, 70 years of age or older, and 80 years of age or older, respectively), with similar trends for prevalence. No major differences were observed among the 14 regions of France for incidence or prevalence. Neovascular age-related macular degeneration incidence in 2018 was not impacted by the availability of primary or ophthalmology care in patients’ localities. Conclusions: The LANDSCAPE study provides exhaustive nationwide data on incidence and prevalence of nAMD in France over a 10-year period. |
| first_indexed | 2024-12-13T09:04:31Z |
| format | Article |
| id | doaj.art-acc5c9c633454a228e86b5e6f9648c3b |
| institution | Directory Open Access Journal |
| issn | 2666-9145 |
| language | English |
| last_indexed | 2024-12-13T09:04:31Z |
| publishDate | 2022-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Ophthalmology Science |
| spelling | doaj.art-acc5c9c633454a228e86b5e6f9648c3b2022-12-21T23:53:06ZengElsevierOphthalmology Science2666-91452022-03-0121100114Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018Catherine P. Creuzot-Garcher, MD, PhD0Mayer Srour, MD1Florian Baudin, MD2Vincent Daien, MD, PhD3Corinne Dot, MD, PhD4Sylvia Nghiem-Buffet, MD5Jean-Francois Girmens, MD6Nicolas Coulombel, MBA7Anne Ponthieux, PhD8Cecile Delcourt, PhD9Department of Ophthalmology, University Hospital, Dijon, FranceDepartment of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, Université de Paris Est Créteil, Créteil, FranceDepartment of Ophthalmology, University Hospital, Dijon, FranceDepartment of Ophthalmology, Gui De Chauliac Hospital, Montpellier, FranceDepartment of Ophthalmology, Desgenettes Military Hospital, Lyon, FranceCentre d’imagerie et de laser, Paris, FranceDepartment of Ophthalmology, INSERM-DGOS CIC 1423, CHNO des Quinze-Vingts, Paris, FranceIQVIA France, La Défense, FranceNovartis Pharma SAS, Rueil-Malmaison, Malmaison, France; Correspondence: Anne Ponthieux, Novartis Pharma SAS, 8/10 rue Henri Sainte Claire Deville, CS 40150, 92563 Rueil-Malmaison CEDEX, France.Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, Team LEHA, Bordeaux, FrancePurpose: This study aimed to estimate the incidence and prevalence of neovascular age-related macular degeneration (nAMD) in the French population between 2008 and 2018. Design: This was a retrospective, longitudinal population study using health care consumption data from the Système National des Données de Santé (SNDS; the French National Health Information Database), which covers approximately 99% of the French population. Participants: We identified individuals treated for nAMD from the French population 50 years of age and older. Identification criteria were nAMD diagnosis or reimbursement of nAMD treatments (anti–vascular endothelial growth factor intravitreal injection or dynamic phototherapy with verteporfin). Exclusion criteria were high myopia, diagnosis of other retinal diseases, and other treatments for macular diseases (dexamethasone implant, laser therapy, etc.). Methods: We calculated incidence and prevalence based on the age-matched general population in France. Adjustment for age and sex was also performed for incidence. Main Outcome Measures: Incidence and prevalence of nAMD in the French population between 2008 and 2018. Results: Between 2008 and 2018, we identified 342 961 patients with nAMD (67.5% women). Mean ± standard deviation age at nAMD diagnosis or first treatment increased from 78.8 ± 8.1 years in 2008 to 81.2 ± 7.9 years in 2018. In 2018, annual incidence was 0.149% and prevalence was 1.062% for the French population 50 years of age or older. Incidence was stable over the 10-year period. Annual incidence increased with age (0.223%, 0.380%, and 0.603% in those 60 years of age or older, 70 years of age or older, and 80 years of age or older, respectively), with similar trends for prevalence. No major differences were observed among the 14 regions of France for incidence or prevalence. Neovascular age-related macular degeneration incidence in 2018 was not impacted by the availability of primary or ophthalmology care in patients’ localities. Conclusions: The LANDSCAPE study provides exhaustive nationwide data on incidence and prevalence of nAMD in France over a 10-year period.http://www.sciencedirect.com/science/article/pii/S2666914522000033Age-related macular degenerationFranceIncidenceNeovascularPrevalence |
| spellingShingle | Catherine P. Creuzot-Garcher, MD, PhD Mayer Srour, MD Florian Baudin, MD Vincent Daien, MD, PhD Corinne Dot, MD, PhD Sylvia Nghiem-Buffet, MD Jean-Francois Girmens, MD Nicolas Coulombel, MBA Anne Ponthieux, PhD Cecile Delcourt, PhD Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018 Ophthalmology Science Age-related macular degeneration France Incidence Neovascular Prevalence |
| title | Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018 |
| title_full | Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018 |
| title_fullStr | Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018 |
| title_full_unstemmed | Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018 |
| title_short | Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018 |
| title_sort | incidence and prevalence of neovascular age related macular degeneration in france between 2008 and 2018 |
| topic | Age-related macular degeneration France Incidence Neovascular Prevalence |
| url | http://www.sciencedirect.com/science/article/pii/S2666914522000033 |
| work_keys_str_mv | AT catherinepcreuzotgarchermdphd incidenceandprevalenceofneovascularagerelatedmaculardegenerationinfrancebetween2008and2018 AT mayersrourmd incidenceandprevalenceofneovascularagerelatedmaculardegenerationinfrancebetween2008and2018 AT florianbaudinmd incidenceandprevalenceofneovascularagerelatedmaculardegenerationinfrancebetween2008and2018 AT vincentdaienmdphd incidenceandprevalenceofneovascularagerelatedmaculardegenerationinfrancebetween2008and2018 AT corinnedotmdphd incidenceandprevalenceofneovascularagerelatedmaculardegenerationinfrancebetween2008and2018 AT sylvianghiembuffetmd incidenceandprevalenceofneovascularagerelatedmaculardegenerationinfrancebetween2008and2018 AT jeanfrancoisgirmensmd incidenceandprevalenceofneovascularagerelatedmaculardegenerationinfrancebetween2008and2018 AT nicolascoulombelmba incidenceandprevalenceofneovascularagerelatedmaculardegenerationinfrancebetween2008and2018 AT anneponthieuxphd incidenceandprevalenceofneovascularagerelatedmaculardegenerationinfrancebetween2008and2018 AT ceciledelcourtphd incidenceandprevalenceofneovascularagerelatedmaculardegenerationinfrancebetween2008and2018 |